The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

December 05, 2013

Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses the role of ipilimumab in bladder cancer.

November 25, 2013

Immunotherapy can induce regressions of even advanced stage cancers, and many of these patients can have prolonged disease remissions.

November 15, 2013

Matthew D. Galsky, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, explains the mechanism of action of ipilimumab in bladder cancer.

October 30, 2013

Intervention doubled palliative care consultations; lowered in-hospital mortality and hospital readmission rates.

August 23, 2013

Over the past several years, several new approaches to treatment have prolonged and improved quality of life for patients with metastases.

August 07, 2013

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

July 22, 2013

Over the past decade, it has become apparent that head and neck squamous cell carcinoma-including cancers of the mouth, throat, and larynx-is actually two separate diseases.

April 05, 2013

There have been waves of advancements in the treatment of multiple myeloma and further exploration of existing regimens and research into novel therapeutics hold the promise of advances.

February 18, 2013

Drs William Oh and Yixuan Gong discuss their research involving a whole-blood, 6-gene prognostic signature that has the potential to help personalize prostate cancer treatment.

January 14, 2013

Randall F. Holcombe, MD, Tisch Cancer Institute at Mount Sinai Medical Center, speaks about the use of aflibercept in patients with metastatic colorectal cancer.

January 08, 2013

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses ongoing research into combination strategies for men with castration-resistant prostate cancer.

January 02, 2013

More potent versions of existing therapies are currently under development and showing considerable promise in early clinical trials for patients with multiple myeloma.

December 26, 2012

Over the past decade, the availability of new agents with varying mechanisms of action has greatly enhanced the treatment landscape in castration-resistant prostate cancer.

November 12, 2012

William K. Oh, MD, from the Tisch Cancer Institute, discusses strategies for sequencing the new therapies that have been approved for treating castration-resistant prostate cancer.

October 11, 2012

A whole-blood prognostic test based on gene-expression signatures may help predict risk for patients with castration-resistant prostate cancer.

March 12, 2012

Dr. Sundar Jagannath, from Mount Sinai Medical Center, Discusses the VANTAGE Trials

January 04, 2012

Dr. Marshall Posner, from Mount Sinai Medical Center, Discusses the Link Between HPV and Cancer